1 Title

2 Multiomic analyses uncover immunological signatures in kidney transplantation

3

4 Author list

- 5 Claire Tinel^{1,2,3}, Alexis Varin², Dany Anglicheau^{4,5}, Jasper Callemeyn^{1,6}, Jetty De Loor¹, Wilfried
- 6 Gwinner⁷, Pierre Marquet⁸, Marion Rabant^{4,9}, Virginia Sauvaget⁴, Elisabet Van Loon^{1,6},
- 7 Baptiste Lamarthée^{1,2, ϕ ,*, Maarten Naesens^{1,6, ϕ}}
- 8

9 Affiliations

- 10 ¹Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney
- 11 Transplantation Research Group, KU Leuven, Leuven, Belgium
- 12 ²University of Franche-Comté, Inserm UMR Right, Établissement Français du Sang,
- 13 Besançon, France
- ³Departement of Nephrology and Kidney Transplantation, Dijon University Hospital, University
- 15 of Bourgogne, Dijon, France
- ⁴Departement of Nephrology and Kidney Transplantation, Necker Hospital, Paris, France
- ⁵University Paris Cité, Inserm U1151, Necker Enfants-Malades Institute, Paris, France
- ⁶Department of Nephrology and Kidney Transplantation, University Hospital Leuven, Leuven,
- 19 Belgium
- ⁷Department of Nephrology, Hannover Medical School, Hannover, Germany
- ⁸Department of Pharmacology and Transplantation, University of Limoges, Inserm U1248,
- 22 Limoges University Hospital, Limoges, France
- ⁹Departement of Pathology, Necker Hospital, Paris, France

24

- 25
- 26 [•]These authors contributed equally
- 27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 28 *Corresponding author:

- 29 Baptiste Lamarthée, PhD
- 30 Phone: +33 81 61 56 15
- 31 Rue du Docteur Girod, 25000 Besançon, France
- 32 Email: baptiste.lamarthee@inserm.fr
- 33
- 34

35 Abstract

36 Identifying biomarkers in kidney transplant patients is essential for early detection of rejection, 37 personalized treatment and improved overall outcomes. It improves our ability to monitor the 38 health of the transplanted organ and tailor interventions to the specific needs of each patient. 39 Here we compiled a multicenter, multiomic dataset of the kidney transplant landscape. Using 40 multi-omics factor analysis (MOFA), we sought to uncover sources of biological variability in 41 patients' blood, urine and allograft at the epigenetic and transcriptomic levels. MOFA reveals 42 multicellular immune signatures characterized by distinct monocyte, natural killer and T cell 43 substates explaining a large proportion of inter-patient variance. We also identified specific 44 factors that reflect allograft rejection, complement activation or induction treatment. Factor 1 45 mainly explained the molecular variations in patients' circulation and discriminated antibody-46 mediated rejection from T-cell mediated rejection. Factor 2 captured some of the molecular 47 variation occurring within the allograft and associated with complement/monocytes crosstalk. 48 Factor 4 captured the impact of ATG induction. These data provide proof-of-concept of 49 MOFA's ability to reveal multicellular immune profiles in kidney transplantation, opening up 50 new directions for mechanistic, biomarker and therapeutic studies.

51

52

53 Introduction

54

55 Kidney transplantation is the treatment of choice for patients with end-stage renal 56 disease, offering a significant improvement in quality of life and a reduction in morbidity and 57 mortality. However, the long-term success of renal transplantation depends on many factors, 58 such as immunological compatibility between donor and recipient, optimal management of 59 immunosuppressive therapies and early detection of any signs of rejection or post-transplant 60 complications. In kidney transplantation, both immune and non-immune mechanisms 61 contribute to the progression of histological lesions and scarring of the kidney graft. These lesions, resulting from complex interactions between immune cells, soluble molecules and 62 63 graft architecture, compromise graft function and long-term survival.

64

The objectives of the BIOMARGIN study were to discover biomarkers of renal allograft 65 lesions derived from biopsies, blood and/or urine. To achieve these objectives, the 66 67 BIOMARGIN consortium employed an ambitious strategy involving a succession of clinical 68 studies in 4 hospitals in three European countries for the discovery, confirmation and validation 69 of biomarkers in which transplant patients provided blood, urine and biopsy samples. Large-70 scale supervised explorations, also known as "omics", of these biological samples separately 71 using state-of-the-art analytical technologies led to the discovery of several biomarkers or 72 insights in kidney transplantation $^{1-5}$.

73

In addition, recent advances in omics technologies have led to unprecedented efforts to characterize the molecular changes underlying the pathophysiology of a wide range of complex human diseases such as coronary syndrome recently⁶. The combination of different omics technologies, called "multi-omics" analyses, has been proposed to decipher the molecular mechanisms involved in complex diseases. These analyses can be classified into supervised and unsupervised methods. The aim of supervised methods is to predict one or more conditions related to a sample, although over-fitting can be an issue. In contrast, 81 unsupervised methods explore the data by analyzing correlations between samples in order 82 to condense the large volume of data into a reduced number of factors which, in turn, could be 83 associated with clinical features. MOFA2 (Multiple Omics Factor Analysis version 2) is an 84 unsupervised statistical approach developed to explore and integrate multiple omics data sources such as genomics, transcriptomics, proteomics and metabolomics⁷. In the present 85 report, we used MOFA2 to uncover specific biological signatures associated with kidney 86 transplant phenotypes and outcomes by identifying complex patterns and relationships 87 88 between different molecular variables such as mRNA and miRNA from biopsies, blood and 89 urine.

90

91 Results

92 MOFA application on BIOMARGIN datasets

93 We collected data from blood, biopsy and urine samples of 131 kidney transplant recipients 94 comprising six data types (also called views): 1 blood-derived epigenome (miRNA expression), 95 2 blood-derived transcriptomes (mRNA quantified by MicroArray, mRNA quantified by RNA 96 sequencing), 1 biopsy-derived epigenome (miRNA expression), 1 biopsy-derived 97 transcriptome (mRNA quantified by MicroArray) and 1 urine-derived selected gene set (mRNA 98 quantified by RT-qPCR). In blood, a total of 58828 genes were measured by RNAseq, 54675 99 genes were detected by MicroArray and 758 miRNAs were measured by RT-gPCR. In biopsy, 100 54613 genes were assessed by MicroArray and 758 miRNAs were measured by RT-qPCR. In 101 urine, 34 genes were measured by RT-qPCR (Figure 1a). Given these 6 data matrices with 102 measurements of multiple omics data types across sample sets or partially overlapping sample 103 sets, MOFA infers an interpretable low-dimensional data representation of factors. These 104 learned factors capture the main sources of variation between views, facilitating the 105 unsupervised identification of continuous molecular gradients or discrete sample subgroups 106 (Figure 1a). In order to integrate the various omics data with MOFA, we constructed 131 107 multiomics profiles by matching samples in the 6 views. It should be noted that only 26.7% 108 (N=35) of the 131 samples were profiled with all types of omics data mainly due to the limited

number of samples with mRNA data for urine (Figure 1b), but such a scenario of missing
values is not uncommon in multidimensional cohort studies and MOFA is designed to cope
with it⁷.

112

113 As it is recommended to perform a stringent selection of features before creating the MOFA 114 object, we performed an initial selection of features from the Blood RNA-seq, Blood miRNAs 115 and Biopsy miRNAs, keeping only the top 25% of genes with the greatest variance (First 116 features selection). Integrating these features with MOFA resulted in an over-representation 117 of transcriptome views at the expense of epigenome views (Figure S1a). Secondly, to ensure 118 that epigenome views were not under-represented when fitting MOFA, we removed weakly 119 expressed features from transcriptomic views and filtered out the least expressed genes 120 (Second features selection). This selection resulted in a more balanced representation of 121 blood-derived miRNAs, but did not improve the representation of biopsy-derived miRNAs (% 122 explained variance < 5%, Figure S1a). Thirdly, we followed a strategy recommended by the 123 MOFA authors to adjust the number of transcriptome features, selecting the 5000 genes with 124 the greatest variability measured by standard deviation but also taking into account all 125 epigenomic features. We observed that estimating MOFA with a greater number of epigenomic 126 features led to a significant increase in the percentage of variance explained in the epigenome 127 and to a more balanced final features selection. (Figure S1a and Figure 1c).

128

129 To obtain a MOFA model with this final features selection, we trained MOFA 100 times. We 130 chose the MOFA model with the lowest absolute Evidence Lower Bound (ELBO) value to strike 131 a balance between model complexity and explanatory power (Figure S1b). MOFA identified 8 132 factors that were largely orthogonal, capturing independent sources of variation. Cumulatively, 133 the 8 factors explained 38% of the variation in blood-RNAseg data, 61% in blood-MicroArray 134 data, 27% in blood-epigenome data, 42% in biopsy-transcriptome data, 23% in biopsyepigenome data and 2.9% in urine data (Figure 1c). Of these, Factor 2 and Factor 3 were 135 136 active in most assays (Figure 1d), indicating extensive roles in multiple molecular layers in

137 both the transplanted kidney and the circulation. In addition, other factors such as Factor 1 and Factor 4 were specific to blood-related views. The fact that most of the factors explain the 138 139 variance between several views indicates that the data are very highly correlated between 140 views, and that it is possible to identify common patterns between different omics views. In contrast, Factor 6, Factor 7 and Factor 8 were mainly active in only one data modality which 141 diminishes their interest in this multiomics approach (Figure 1d). We next estimated the 142 143 correlation between factors and observed correlations R² below 0.4 indicating that each factor 144 captures independent and unique sources of variations (Figure S1c).

145

146 MOFA identifies important clinical markers in kidney transplantation

147 To understand how factors relate to kidney transplant phenotypes, we assessed the 148 relationship between factor loadings and different kidney transplant outcome parameters 149 (Figure 1e). Patient characteristics are shown in Supplemental Table 2. Intriguingly, some 150 factors correlated exclusively with Banff histological lesions or complement activation: Factor 151 2 was positively correlated with C4d deposition in peritubular capillaries ("C4d positivity"; P value<0.001) while Factor 5 was associated with C4d positivity (R²<0, P value<0.0001), tubular 152 atrophy ("ct"; R²>0, P value<0.01), interstitial fibrosis ("ci"; R²>0, P value<0.001) and arteriolar 153 154 hyalinosis ("ah"; R²>0, P value<0.01). In contrast, Factor 3 and Factor 8 correlated uniquely 155 with certain causes of renal failure (interstitial nephritis, R²>0, P value<0.001 and hypertension, 156 R^{2} <0, P value <0.0001 respectively). Factor 4 was strongly associated with 157 immunosuppression: it was negatively correlated with ATG induction (P value < 0.0001) and 158 positively correlated with tacrolimus immunosuppression (P value <0.01). In addition, certain 159 factors were associated with multiple parameters of varying natures. Factor 7 was negatively associated with diabetes as a cause of renal failure (P value<0.01), creatinine (P 160 value<0.0001), anti-HLA DSA (P value<0.01), g lesions (P value<0.01) and v lesions (P 161 value<0.00001). Factor 1 correlated with eGFR (R²<0, Pearson correlation P value<0.01), anti-162 163 HLA DSA (R²<0, P value<0.001), transplant glomerulopathy ("cg"; R²<0, P value<0.01) and total inflammation ("ti"; R²>0, P value<0.01). Lastly, Factor 6 was associated with 164

165 glomerulonephritis as a cause of kidney failure ($R^2>0$, Pearson correlation P value<0.01), 166 eGFR ($R^2>0$, P value<0.01), erythrocyte titer ($R^2>0$, P value<0.001), leukocyte titer ($R^2<0$, P 167 value<0.001) and ti ($R^2>0$, P value<0.01).

168

169 Factor 1 discriminates antibody-mediated from T-cell mediated rejection

170 Factor 1 mainly explained the molecular variations in blood of kidney transplant recipients (Figure 1d) and was negatively correlated with anti-HLA DSA status. Intriguingly, this blood-171 172 related factor was also associated with cg and ti lesions in the graft (Figure 1e). To confirm 173 these correlations, we assessed the global distribution of Factor 1 loading (Figure 2a), and 174 then explored the distribution of Factor 1 loading according to cg and ti lesion scores. We 175 observed a significant decrease in Factor 1 loading in cases with a cg>0 score (Figure 2b), 176 while Factor 1 loading increased significantly in cases with a ti>1 score (Figure 2c). We also 177 confirmed the significant decrease in Factor 1 loading in the presence of anti-HLA DSA (Figure 178 **2d, Supplemental Table 3).** We also performed univariate logistic regressions and reported 179 the performance of Factor 1 to discriminate HLA-DSA status and the presence of ti lesions and 180 cg lesions by (Figure S2a). Given the increase in Factor 1 loading with ti lesions and the 181 decreases in the presence of HLA-DSA and cg lesions, we tested whether Factor 1 loading 182 differed between cases with antibody-mediated rejection (AMR) and T-cell mediated rejection 183 (TCMR). To this end, we stratified patients according to different phenotypes (AMR, TCMR, 184 Normal and IFTA) and we observed a significant difference between the TCMR and AMR 185 group suggesting that Factor 1 may discriminate TCMR from AMR (Figure 2e).

Features contributing more than 0.9 of the absolute Factor 1 loading mainly derived from blood MicroArray data (D= 11, **Figure 2f**). The other molecules contributing to each view have also been represented in **Figure S2b**. The significant contribution of the blood MicroArray data view to the Factor 1 is reflected in the heatmap, where a clear separation was observed between blood samples (**Figure 2g**). In fact, unsupervised clustering of blood samples using these 11 top features resulted in two main clusters: samples with HLA-DSA were preferentially grouped in Cluster A in which the 11 features were overexpressed (two-tailed Fisher's exact test, P-

193 value = 0.001). For the grouping of cases according to AMR or TCMR phenotypes, the Fisher 194 exact test P-values were 0.0562 and 0.1676 respectively. We then used a publicly available blood RNASeq dataset GSE120649⁸ (Figure S2c) to validate whether these 11 features in 195 196 blood MicroArray and the 3 features contributing more than 0.9 of the absolute Factor 1 loading 197 in blood RNA-Seq would be differentially expressed in AMR and TCMR. Interestingly, 12/14 198 features were found increased in AMR in this dataset (Figure S2d), suggesting that Factor 1 199 could reflect the different immune responses of the two types of rejection in circulating cells. 200 In order to map at the single-cell level the different renal and/or immune cells that could express 201 the top features of Factor 1, we reintegrated 46 publicly available scRNA-Seg datasets from 202 kidney transplant patients, including transcriptomes from both circulating blood cells (PBMC) 203 and cells derived from kidney biopsies (Figure S3a). We were thus able to obtain 150,876 204 transcriptomes which passed quality check (Figure S3b) and, using canonical markers 205 (Figure S3c), to identify 23 clusters corresponding to all renal and circulating cell populations 206 (Figure S4a). For further granularity, a subset corresponding only to circulating cells was 207 selected and 29 clusters were identified and automatically annotated in an unsupervised 208 manner (Figure S4b). We then formed a signature corresponding to the top features 209 explaining Factor 1 in the blood and we observed that the top features of Factor 1 were not 210 centralized in a single immune cell population, but instead scattered across myeloid cells, T, 211 B and NK lymphocytes, and even granulocytes (Figure S4c). More specifically, ZNF267 is 212 preferentially expressed by neutrophils, while MOB1B and TVP23B are derived from basophils 213 and progenitors. CD69, SUCO, SMIM15 and AGL are expressed by lymphocytes, ABCB10 by 214 monocytes and DMXL1, CLK1 and RSL24D1 by B lymphocytes and plasmablasts. Factor 1 215 thus corresponds to a multicellular immune profile that differs between TCMR and AMR in 216 patients' blood.

217

218 Factor 2 is associated with complement/monocytes crosstalk

In contrast to Factor 1, Factor 2 captured some of the molecular variation occurring inside theallograft. Among all the outcomes tested, it was only positively correlated with C4d (Pearson

221 correlation, P-value<0.001) (Figure 1e). Of note, C4d deposition in peritubular capillaries is 222 associated with immune reactions directed against the allograft and are the result of activation 223 of the complement system. To confirm the correlation between C4d positivity and Factor 2, we 224 assessed the global distribution of Factor 2 loading (Figure 3a), and then explored the 225 distribution of Factor 2 loading according to C4d positivity. We observed a significant increase 226 in Factor 2 loading in cases with C4d positivity (Figure 3b). By stratifying patients according 227 to Factor 2 median, a trend towards an increase in the number of C4d-positive cases was also 228 found in patients above the median (Supplemental Table 3). The top features contributing to 229 the absolute Factor 2 loading mainly derived from biopsy MicroArray data (D= 15, Figure 3c). 230 The top features deriving from biopsy MicroArray data and explaining Factor 2 clearly 231 separated the samples into two groups (Figure 3d) in an unsupervised manner. Cases positive 232 for C4d were grouped showed high expression of the top features LYZ, CALHM6, EVI2A, 233 CD52, IGSF6, C1QB, EVI2B, BCL2A1, C1QC, C16orf54, CSTA, CXCL9, CTSS, CXCL10 and 234 TYROBP. Interestingly, two of these features C1QC and C1QB encode the B and C-chains 235 polypeptide of serum complement subcomponent C1q, which associates with C1r and C1s to 236 vield the first component of the serum complement system. With regard to other top features 237 explaining Factor 2 in biopsies, five miRNAs were detected: miR-150, miR-223, miR-1227, 238 miR-624 and miR-155 (Figure S5a). Among the upregulated miRNAs, our group has 239 previously reported that miR-155 is preferentially expressed by monocytes⁴, suggesting that 240 Factor 2 may capture the infiltration of blood monocytes/macrophages into the allograft and 241 the overexpression of complement by these cells. In order to validate the association between 242 these Factor2 top features and C4d deposition in peritubular capillaries in an external dataset, 243 MicroArray data from biopsies of kidney transplant patients with and without C4d were 244 analyzed (Figure 3e). Here, the transcriptomes of 23 C4d-negative biopsies were compared 245 with 16 biopsies showing focal, diffuse or minimal C4d ptc staining (Figure 3f). As shown on 246 the volcano plot, biopsies positive for C4d showed overexpression of both mRNA transcripts 247 and miR-150, miR-223 and miR-155 explaining Factor 2. In the scRNA-Seq dataset, we then 248 formed a signature corresponding to the top features explaining Factor 2 in the kidney and

observed that this signature was particularly strong in myeloid cells (Figure S5b). Strikingly, macrophages were the main cell population expressing the top features (Figure S5c) and more specifically *C1QC* and *C1QB*, suggesting that Factor 2 captured the crosstalk between macrophages and complement activation in the allograft after transplantation.

253

254 Factor 4 captures the impact of induction prophylaxis

255 Similar to Factor 1, Factor 4 captured some of the molecular variation in blood samples (Figure 256 1d). Factor 4 was strongly and negatively correlated with ATG induction (Pearson correlation, 257 P-value<0.00001) and positively correlated with tacrolimus immunosuppression protocol 258 (Figure 1e). Evaluating the overall distribution of Factor 4 loading (Figure 4a), and then 259 exploring the distribution of Factor 4 loading according to induction types, we observed that 260 Factor 4 loading was also reduced in cases that had received ATG as induction compared to 261 no induction (P-value=0.0023) or other induction therapy (Figure 4b, Supplemental Table 5). 262 Considering the top 10 features measured by RNAseg in blood in terms of absolute loading, 263 two clear groups of patients were distinguished in an unsupervised manner: one showing low 264 IL1R2 expression and without patients who had received ATG (N=0/21, 0%), and a second 265 with high *IL1R2* levels including 15/53 patients who had received ATG as induction (28%). 266 Interestingly, among the other top features, expressions of TRBC2, BCL11B, CD3G, CD247, 267 CD3E, STMN3, GIMAP7, FCMR, SRNPN and CCR7 were down-regulated in the group 268 including ATG-treated patients (Figure 4c-d). The advantage of MOFA is to uncover 269 transcriptomic profiles across omics types and tissues. Strikingly, one of the most weighted 270 features explaining Factor 4 in the biopsy is *IL1R2* (Figure S6a).

271

272 Querying the scRNA-Seq dataset, we observed that the other major features were principally 273 expressed by T cells and NK cells (**Figure S6b**). More specifically, naive T cells 274 subpopulations as well as regulatory T cells and central CD8 T cells highly expressed Factor 275 4 top features such as *FCMR*, *CCR7*, *SNRPN* and *BCL11B*. *FCMR* expression was mainly 276 restricted to B cells subpopulation. In addition, we observed that *IL1R2* is predominantly 277 expressed by and myeloid dendritic cells and classical monocytes in the blood (Figure S6c), suggesting a disturbance in the lymphoid/myeloid cell ratio in both patient groups. To validate 278 279 these data, we took advantage of a public GSE10040 dataset corresponding to an in vitro 280 experiment in which PBMCs from healthy volunteers were treated with ATG at 10µg/mL for 281 24h⁹. After culture, cells were harvested and mRNA extracted for full transcriptomic analysis 282 (Figure 4e). We found that ATG treatment induced the differential expression of 4438 genes 283 (DEGs) comprising 2327 down-regulated genes and 2112 up-regulated genes. By mapping 284 the top features of Factor 4 among these 4438 DEGs, we observed that *IL1R2* is strongly 285 induced by ATG treatment (fold change (FC) >3.9 and Log10(pvalue) >6.4) but so is CCR7 286 (FC>0.9, Log10(pvalue) >3.3). In contrast, the other features are mainly down-regulated, such as SNRPN (FC<-0.7, Log10(pvalue) >3.5), CD3E (FC<-0.3, Log10(pvalue) >1.7), FCMR 287 (FC<-0. 9, Log10(pvalue) >2.1), BCL11B (FC<-0.5, Log10(pvalue) >1.8), CD247 (FC<-0.3, 288 289 Log10(pvalue) >1.3), STMN3 (FC<-0.1, ns) and GIMPAP7 (FC<-0.1, ns). Of note, TRCB2 was 290 not detected and CD3G was slightly increased (FC>0.1, ns) (Figure 4f). Overall, these results suggest that ATG treatment induces a strong disruption of the immune system that could be 291 292 detected several months after treatment in blood but also in the allograft, leading to a decrease 293 in the lymphoid compartment in favor of the myeloid compartment.

294

295 Discussion

296 MOFA2 analysis enables researchers to simultaneously combine and analyze high-297 throughput data from different biological sources. This method of analysis is proving 298 particularly valuable in the field of medical research, where it enables us to better understand 299 the complexity of the molecular and cellular interactions involved in complex disease 300 processes. By elucidating these mechanisms, clinicians can better target therapies and improve long-term kidney success. To our knowledge, this is the first time this type of MOFA 301 302 analysis has been conducted in the field of kidney transplantation. Integrating the different 303 omics layers, MOFA2 delimited 8 different factors in an unsupervised manner. As expected, 304 these factors captured independent transcriptomic profiles across blood and renal allografts.

305 Surprisingly, we observed very few associations between histology and the factors. 306 This indicates that rejection phenotypes (according to the Banff classification), but also 307 rejection severity and phenotype patterns such as rejectionclass are not the main drivers of 308 molecular heterogeneity within allografts and in circulation. In fact, only Factor 1 reflects 309 different profiles between HLA-DSA positive and HLA-DSA negative cases.

310 Factor 2 was related to the intragraft crosstalk between monocytes/macrophages and 311 complement. It was associated with C4d deposition independent of rejection status, suggesting that this crosstalk is not specific to the AMR process. Indeed, Factor 2 was not significantly 312 correlated with the presence of HLA-DSA, suggesting that this crosstalk between 313 314 macrophages and complement might be due to non-HLA antibodies which could be detrimental in the context of kidney transplantation¹⁰⁻¹². In fact, interactions between 315 316 monocytes/macrophages and complement factors are multiple and complex, contributing 317 significantly to the innate immune responses. Infiltrating monocytes and tissue-resident macrophages can locally synthesize several components of the complement system, including 318 319 C1, C2, C3, C4, C5, C6, C7, C8, and C9. In particular, we have previously shown that CD163+ 320 macrophages are the main immune cells expressing complement-associated genes such as C1QA, C1QB and C1QC among myeloid cells present in the allograft¹³. In turn, certain 321 322 complement degradation products, such as the C5a fragment via CD88 or C3a via Toll Like Receptors or C4d via LILRB2 and LILRB3¹⁴, act as chemokines, attracting monocytes and 323 324 macrophages and modulating their production of cytokines such as TGF- β 1¹⁵. It is worth noting that urinary *TGFB1* mRNA was the second most important feature (absolute loading>0.95) 325 326 explaining Factor 2, and one could speculate that this urinary detection of TGFB1 mRNA could be due to podocyte lesions¹⁶. At the same time, biopsy-derived miR-155 was also among the 327 328 key features explaining Factor 2. Intriguingly, this miRNA was closely linked to podocyte apoptosis after exposure to TGF-β1¹⁷. Altogether our results suggest that Factor 2 reflects the 329 330 monocytes/macrophages crosstalk with complement within the allograft and that this crosstalk 331 may be associated with podocyte lesions.

332

333 Surprisingly, Factor 4 was significantly associated with the type of induction regimen, suggesting that ATG therapy can affect patients' immune profiles longer term after 334 335 transplantation. It is clear that ATG makes patients more susceptible to infections, both in the short and long term¹⁸. This increased sensitivity may persist even after ATG treatment has 336 337 been discontinued. ATG induction has also been associated with a higher risk of long-term malignancies compared with anti-CD25 induction¹⁹. The top-weighted genes of Factor 4 338 suggest an imbalance in the patient's immune system, with a decrease in the T cell 339 340 compartment in favor of the myeloid compartment both in the circulation and in the allograft.

341

342 This study has several limitations. The datasets used in this study are relatively small, which 343 may limit the ability to capture the full spectrum of variability and complexity present in larger, 344 more diverse populations. Indeed, our study primarily involves Western European centers with 345 a predominantly Caucasian population. This demographic constraint may limit the applicability 346 of our results to other ethnic groups and geographic regions, potentially reducing the overall 347 generalizability of our conclusions. In addition, the analysis in this study is fully dependent on 348 the MOFA2 algorithm. While MOFA2 is a powerful tool for integrative analyses, relying 349 exclusively on this algorithm means that other integrative approaches might yield different 350 factors and insights. This dependence highlights the need for comparative studies using 351 alternative methodologies to validate our findings. Although we conducted systematic 352 validation on external datasets for each factor of insterest, our study lacks in-depth mechanistic 353 studies to confirm the identified factors with greater certainty.

354

In conclusion, MOFA2 analysis represents a major advance in the integration of omics data to understand kidney transplantation. Our study highlights the significant associations between factors and clinical parameters. This highlights MOFA as an innovative approach to dissect multicellular immune profiles with mechanistic and clinical implications in kidney transplantation. Furthermore, our study, as a globally available resource, provides new targets

360 for large-scale MOFA-based experimental studies and biomarker assays, and helps prioritize

361 new candidate targets for immunomodulatory interventions in kidney transplantation.

362

363 Methods

364 Patient population and data collection

365 The present study is part of the Reclassification using OmiCs integration in KidnEy Transplantation (ROCKET) project, which is based on the BIOMArkers of Renal Graft INjuries 366 367 (BIOMARGIN) study (ClinicalTrials.gov number NCT02832661). Patients were included 368 prospectively in four European transplant centers between June 2011 and March 2017 369 (University Hospitals Leuven, Belgium; Medizinische Hochschule Hannover, Germany; Centre 370 Hospitalier Universitaire Limoges, France, and Hôpital Necker Paris, France). In all four clinical 371 centers, protocol renal allograft biopsies were performed 3, 12 and sometimes 24 months after 372 transplantation, in accordance with local practice, in addition to clinically indicated biopsies 373 (biopsies at the time of graft dysfunction). In parallel, blood and urine samples were collected 374 at the same times. All adult patients who had received a single renal allograft at these 375 institutions and provided written informed consent for this study were eligible. This consent 376 adheres to the Declaration of Istanbul. Ethics committee XI #13016, Paris, France for Necker 377 Hospital gave ethical approval for this work. Ethics committee #S55598, Leuven, Belgium for 378 Leuven Hospital gave ethical approval for this work. Ethics committee #6475, Hannover, 379 Germany for Hannover Medical School gave ethical approval for this work. Ethics committee 380 #DC-2010-1075, Limoges, France for Limoges Hospital gave ethical approval for this work. 381 Recipients of combined transplantations were excluded. All transplantations were 382 complement-dependent cytotoxicity cross-match negative. The study protocol was approved 383 by institutional review boards and national regulatory agencies (where applicable) at each 384 clinical center. The BIOMARGIN study was divided into three phases. Only data from the first 385 exploratory phase are used in the present report. In this discovery phase, blood samples were 386 used for an epigenome analysis (miRNA expression [E-MTAB-9595]⁵) and two transcriptome 387 analyses (mRNA guantified by MicroArray [GSE129166]¹, and bulk RNA sequencing [GSE175718]³). In parallel, biopsy samples were used for an epigenome analysis (miRNA expression [GSE179772]⁴) and a transcriptome analysis (mRNA quantified by MicroArray [GSE147089]²). With the exception of urinary mRNA, each dataset is publicly available, and details of RNA extractions and RNA expression analysis are extensively detailed in the corresponding reports.

393

394 Urinary mRNA quantification

395 For mRNA quantified in urine, samples were centrifuged for 20 min at 2,000g at 4°C. The cell pellet was resuspended in 700µL of PBS and centrifuged for 5 min on a tabletop centrifuge at 396 397 maximum speed. PBS was discarded and cells were resuspended in 500µL RLT buffer 398 (Qiagen, Courtaboeuf, France) in a cryotube before being frozen at -80°C. MessengerRNA 399 was extracted from the pellet using the RNeasy mini kit (Qiagen) and reverse transcribed into 400 cDNA using TagMan® reverse transcription reagents (Applied Biosystems). We used in-house 401 designed oligonucleotide primers and fluorogenic probes to measure mRNA levels of 402 ribosomal RNA 18S, ACTA2, ENG, CD14, CD3E, CD46, CFB, CXCL13, CXCL9, CXCL10, 403 IL2RA, CDH1, FN1, FOXP3, GZMB, GAPDH, HGF, PRF1, PSMB9, PSMB10, SLC12A1, 404 TGFB1, TLR4 and VIM as detailed in Supplementary Table 1 or commercial assays 405 (Thermofisher) for CTSS (Hs00175407 m1), GNLY (Hs00246266 m1), FCGR3A 406 (Hs00275547 m1), (Hs00158122 m1), ISG20 KLRD1 (Hs00233844_m1), MMP7 407 (Hs01042796 m1), MMP9 (Hs00957562 m1), NKG2D (Hs00183683 m1), NKG7 (Hs01120688 g1), RUNX3 (Hs00231709 m1), and UPK1A (Hs01086736 m1). PCR analysis 408 was performed in two steps, a pre-amplification step as described previously²⁰ (Veriti 96-Well 409 410 Thermal Cycler, Applied Biosystems) followed by mRNA measurement with a Viia 7 Real-Time 411 PCR system (Thermofisher). GAPDH was used as housekeeping gene²¹ for normalization 412 using the delta Ct method. The normalized expression was log transformed before MOFA 413 integration.

414 Data processing and filtering

415 Both blood- and biopsy-derived miRNA expressions were determined as previously described^{4,5} using two small-nucleolar RNAs for normalization: RNU44 and RNU48. The 416 417 normalized expressions were log transformed before MOFA integration. Blood- and biopsy-418 derived transcriptomes quantified by MicroArray were subjected to Robust Multichip Average (RMA) normalization as previously described^{1,2}. These datasets were then curated and 419 420 annotated using the Biological Interpretation Of Multiomics EXperiments (BIOMEX) workflow²² before MOFA integration. Raw counts corresponding to the blood-derived transcriptome 421 guantified by bulk RNA sequencing were filtered to exclude weakly expressed genes (with <5 422 counts in 50% of the samples). After filtration, the data were subjected to normalization by 423 variance stabilizing transformation (VST) using the R package DamiRseq (2.1.0)²³ prior to 424 425 MOFA integration.

426

427 Multiple Omics Factor Analysis version 2

To integrate the six datasets, we used the R package MOFA2 (1.8.0). MOFA is an 428 429 unsupervised machine learning method that identifies latent factors that capture biological 430 sources of variability in multi-omics datasets. It should be noted that clinical covariates were 431 not used to train the model. Data, model and learning options were left default. MOFA was run with 100 iterations in 'slow' convergence mode to ensure model convergence; the final model 432 433 converged after 61 iterations. Interpretation of the factors is analogous to that of the principal 434 components and the relationship between clinical covariates and MOFA factors was analyzed a posteriori. 435

436

437 Clinicopathological diagnosis of acute rejection subtypes

Two kidney biopsy cores were obtained using a 14-gauge needle under sonographic guidance.
One biopsy core was fixed in formalin and embedded in paraffin for standard histopathological
assessment. Half of the second biopsy core was used for frozen sections and/or electron
microscopy; the remaining half core was used for epigenome and transcriptome analyses. All

biopsies were scored according to the internationally standardized Banff 2017 lesion scores²⁴.
The follow-up of anti-HLA antibodies and annotation of donor-specific antibodies (DSA) was
systematically monitored in the histocompatibility laboratory referent of each inclusion center.
A diagnostic label was awarded to each biopsy based on the presence and severity of these
histological lesions and on the DSA status, in concordance with the Banff 2017 classification.

447

448 Single-cell RNA-Sequencing (scRNA-Seq) validation

449 We reintegrated 46 publicly available scRNA-Seq datasets corresponding to kidney transplant 450 biopsies or peripheral blood mononuclear cells (PBMCs) from patients presenting allograft 451 rejection or not, whose raw data were downloaded from various repositories: E-MTAB-11450 ²⁵, E-MTAB-12051 ²⁶, GSE140989 ²⁷, GSE145927 ²⁸, GSE171374 ²⁹, PRJNA974568 ³⁰. Seurat 452 453 R package (v5.0.1) was used to read, create and merge all raw counts matrices into a single 454 object, which was subjected to the following QC parameters: number of features (genes) 455 between 300 and 10,000 per cell and percent of total counts from mitochondrial genes, as 456 defined by the prefix « MT- », below 10% for cells from PBMCs datasets, and below 25% for 457 cells from kidney transplant biopsies datasets.

458 A total of 151.862 cells and 40.353 genes successfully passed QC. Data were log-normalized. 459 scaled, the top 2000 variable features as well as the top 50 Principal Component (PC) 460 dimensions were calculated prior to integration using Reciprocal Principal Component Analysis 461 (RPCA) method, with GSM4339779 and pbmc5 as references and all other datasets as 462 queries on a supercomputer (Mésocentre de calcul de Franche-Comté). Uniform Manifold 463 Approximation and Projection (UMAP) dimensionality reduction was calculated from the top 464 50 PC dimensions, and a resolution of 0.47 was used for unsupervised clustering. scDblFinder 465 R package (v1.16.0) was used for doublets discrimination (as defined by clusters composed 466 of two or more different cells captured in a droplet and sequenced). Kidney-derived clusters annotation was made using already-described canonical markers^{25–36}. PBMC-derived clusters 467 468 automatic annotation was performed using SingleR (v2.4.1) and celldex (v1.12.0) R packages

and MonacolmmuneData as reference dataset ³⁷. Seurat, scCustomize ³⁸ (v2.0.1) and
 RightSeuratTools ³⁹ (v1.0.1) R packages were used for data visualization.

471

472 Whole Transcriptomic external validations

473 Various external datasets were used to validate the top features explaining the factors474 determined by MOFA.

a) External validation of Factor 1 top-weighted genes

To validate the potential for discrimination between AMR and TCMR patients by the topweighted Factor-1-related genes, an external blood-derived transcriptomic dataset, GSE120649⁴⁰, was used. This dataset includes bulk RNAseq analysis of whole blood cells isolated from 6 patients with histologically verified AMR and 4 patients with histologically verified TCMR after kidney transplantation. In brief, the BIOMEX pipeline was used to determine differentially expressed genes between the two patient groups.

482 b) External validation of Factor 2 top-weighted genes

483 To validate the potential for discrimination between C4d negative biopsies and C4d postitive 484 biopsies by the top-weighted Factor-2-related genes, an external kidney allograft-derived transcriptomic dataset, E-GEOD-38262⁴¹, was used. This dataset includes 92 microarray 485 486 datasets corresponding to kidney transplant biopsies from patients divided into seven groups 487 classified according to their histopathological scores, whose raw data (CEL files) were 488 downloaded from ArrayExpress (https://www.ebi.ac.uk/biostudies/arrayexpress/). oligo (1.66.0), hugene10sttranscriptcluster.db (8.8.0), hugene10stprobeset.db (8.8.0) and 489 490 pd.hugene.1.0.st.v1 (3.14.1) R packages were used to read raw data and normalize 491 expression, as well as to convert genes names from Affymetrix HuGene 1.0 st Probe IDs into 492 ENSEMBL IDs. The expression matrix was subsequently analyzed using the BIOMEX pipeline. 493 Here we selected only samples of interest corresponding to biopsy transcriptomes showing 494 minimal, diffuse or focal C4d deposition in the absence of glomerular disease (N=25) or 495 absence of C4d and glomerular disease (N=17). After PCA analysis, 3 outlier samples were

496 excluded (GSM937601, GSM937665, GSM937666) and genes differentially expressed
497 between the 2 groups were calculated.

498 c) External validation of Factor 4 top-weighted genes

To validate the differential expression of top-weighted genes of Factor 4 according to ATG 499 treatment, an external transcriptomic dataset GSE10040⁴², was used. This dataset includes a 500 501 MicroArray analysis of PBMC isolated from healthy volunteers and in vitro treated with or 502 without ATG (10µg/mL), whose raw data (CEL files) were downloaded from Gene expression 503 Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10040). affy (1.70.0), 504 hgu133plus2.db (3.13.0), and limma (3.48.3) R packages were used to read raw data and 505 normalize expression, as well as to annotate genes into ENSEMBL IDs. The expression matrix 506 was subsequently analyzed using the BIOMEX pipeline. In brief, the BIOMEX pipeline was 507 used to determine which genes were differentially expressed between the two experimental 508 groups.

509

510 Statistical analysis

We report descriptive statistics using mean and standard deviation (or median and interquartile range for skewed distributions) for continuous variables or numbers, and percentages for discrete variables, for the full cohort and for the rejection subgroups. We used R Studio (2023.06.1+524) and GraphPad Prism (v10; GraphPad Software, San Diego, CA, United States) for statistical analysis and data presentation. The volcano plots were constructed using the R packages ggplot2 (3.4.1) and ggrepel (0.9.3) and were used to annotate the genes of interest.

518

519 Data availability

All data presented in this present study are derived from the BIOMARGN study and are already publicly available, with the exception of urinary gene expression, which can be shared upon reasonable request. Epigenome analyses were performed using the following datasets: bloodderived miRNA expression E-MTAB-9595 and biopsy-derived miRNA expression GSE179772.

- 524 Blood-derived transcriptome analyses were performed using the following datasets:
- 525 MicroArray-quantified mRNA GSE129166 and bulk RNA sequencing GSE175718. Biopsy-
- 526 derived transcriptome analysis was performed using the following dataset: GSE147089.

527 Code availability

- 528 Code for MOFA2 is available at https://biofam.github.io/MOFA2/.
- 529

530 References

- Van Loon, E. *et al.* Development and validation of a peripheral blood mRNA assay for
 the assessment of antibody-mediated kidney allograft rejection: A multicentre,
 prospective study. *EBioMedicine* 46, 463–472 (2019).
- Callemeyn, J. *et al.* Transcriptional Changes in Kidney Allografts with Histology of
 Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. *J Am Soc Nephrol* **31**, 2168–2183 (2020).
- Van Loon, E. *et al.* Biological pathways and comparison with biopsy signals and cellular
 origin of peripheral blood transcriptomic profiles during kidney allograft pathology.
 Kidney Int (2022) doi:10.1016/j.kint.2022.03.026.
- 540 4. Tinel, C. *et al.* Integrative Omics Analysis Unravels Microvascular Inflammation-541 Related Pathways in Kidney Allograft Biopsies. *Front Immunol* **12**, 4595 (2021).
- 542 5. Tinel, C. *et al.* Modulation of Monocyte Response by MicroRNA-15b/106a/374a
- 543During Antibody-mediated Rejection in Kidney Transplantation. Transplantation 107,5441089–1101 (2023).
- 5456.Pekayvaz, K. *et al.* Multiomic analyses uncover immunological signatures in acute and546chronic coronary syndromes. *Nat Med* **30**, 1696–1710 (2024).
- 547 7. Argelaguet, R. *et al.* Multi-Omics Factor Analysis—a framework for unsupervised
 548 integration of multi-omics data sets. *Mol Syst Biol* 14, (2018).
- Matz, M. *et al.* The regulation of interferon type I pathway-related genes RSAD2 and
 ETV7 specifically indicates antibody-mediated rejection after kidney transplantation.
 Clin Transplant 32, e13429 (2018).
- 552 9. Feng, X. *et al.* Rabbit ATG but not horse ATG promotes expansion of functional CD4
 553 CD25 high FOXP3 regulatory T cells in vitro. doi:10.1182/blood-2008.
- Delville, M. *et al.* Early acute microvascular kidney transplant rejection in the absence
 of anti-HLA antibodies is associated with preformed IgG antibodies against diverse
 glomerular endothelial cell antigens. *Journal of the American Society of Nephrology* **30**, 692–709 (2019).
- Lebraud, E., Eloudzeri, M., Rabant, M., Lamarthée, B. & Anglicheau, D. Microvascular
 Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms. *Front Immunol* 13, (2022).
- Lamarthée, B. *et al.* CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial
 Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant
 Recipients. *Journal of the American Society of Nephrology* **32**, 3231–3251 (2021).

564	13.	Lamarthee, B. et al. Transcriptional and spatial profiling of the kidney allograft
565		unravels a central role for FcyRIII+ innate immune cells in rejection. Nat Commun
566		2022.07.07.22276374 (2023) doi:10.1038/s41467-023-39859-7.
567	14.	Hofer, J. et al. Ig-like transcript 4 as a cellular receptor for soluble complement
568	4 -	fragment C4d. FASEB J 30 , 1492–503 (2016).
569	15.	Gu, H. et al. Crosstalk between IGF-β1 and complement activation augments
570		epithelial injury in pulmonary fibrosis. FASEB J 28 , 4223–34 (2014).
5/1	16.	Fukuda, A. <i>et al.</i> Urinary podocyte and IGF-B1 mRNA as markers for disease activity
572		and progression in anti-glomerular basement membrane nephritis. <i>Nephrology</i>
573		Dialysis Transplantation 32 , 1818–1830 (2017).
574	17.	Lin, X. <i>et al.</i> Role of MiR-155 Signal Pathway in Regulating Podocyte Injury Induced by
575	_	TGF-β1. Cellular Physiology and Biochemistry 42 , 1469–1480 (2017).
576	18.	Brennan, D. C. et al. Rabbit antithymocyte globulin versus basiliximab in renal
577		transplantation. N Engl J Med 355 , 1967–77 (2006).
578	19.	Wang, K., Xu, X. & Fan, M. Induction therapy of basiliximab versus antithymocyte
579		globulin in renal allograft: a systematic review and meta-analysis. <i>Clin Exp Nephrol</i> 22,
580		684–693 (2018).
581	20.	Anglicheau, D. et al. Discovery and Validation of a Molecular Signature for the
582		Noninvasive Diagnosis of Human Renal Allograft Fibrosis. Transplantation 93, 1136–
583		1146 (2012).
584	21.	Galichon, P. et al. Urinary mRNA for the Diagnosis of Renal Allograft Rejection: The
585		Issue of Normalization. American Journal of Transplantation 16 , 3033–3040 (2016).
586	22.	Taverna, F. <i>et al.</i> BIOMEX: an interactive workflow for (single cell) omics data
587		interpretation and visualization. Nucleic Acids Res 48, W385–W394 (2020).
588	23.	Chiesa, M., Colombo, G. I. & Piacentini, L. DaMiRseq—an R/Bioconductor package for
589		data mining of RNA-Seq data: normalization, feature selection and classification.
590		Bioinformatics 34 , 1416–1418 (2018).
591	24.	Haas, M. et al. The Banff 2017 Kidney Meeting Report : Revised diagnostic criteria for
592		chronic active T cell – mediated rejection , antibody- mediated rejection , and
593		prospects for integrative endpoints for next- generation clinical trials. American
594		Journal of Transplantation 18 , 293–307 (2018).
595	25.	Van Loon, E. et al. Biological pathways and comparison with biopsy signals and cellular
596		origin of peripheral blood transcriptomic profiles during kidney allograft pathology.
597		Kidney Int 102 , 183–195 (2022).
598	26.	Lamarthée, B. et al. Transcriptional and spatial profiling of the kidney allograft
599		unravels a central role for FcyRIII+ innate immune cells in rejection. Nat Commun 14,
600		(2023).
601	27.	Menon, R. et al. Single cell transcriptomics identifies focal segmental
602		glomerulosclerosis remission endothelial biomarker. JCI Insight 5, (2020).
603	28.	Malone, A. F. et al. Harnessing Expressed Single Nucleotide Variation and Single Cell
604		RNA Sequencing to Define Immune Cell Chimerism in the Rejecting Kidney Transplant.
605		Journal of the American Society of Nephrology 31 , 1977–1986 (2020).
606	29.	Cormican, S. et al. Chronic Kidney Disease Is Characterized by Expansion of a Distinct
607		Proinflammatory Intermediate Monocyte Subtype and by Increased Monocyte
608		Adhesion to Endothelial Cells. Journal of the American Society of Nephrology 34, 793-
609		808 (2023).

610 30. Shi, T. et al. Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality. Journal of Clinical Investigation 133, (2023). 611 612 Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human 31. 613 kidney. Nature 619, 585-594 (2023). 614 Stewart, B. J. et al. Spatio-temporal immune zonation of the human kidney Europe 32. 615 PMC Funders Group. 365, 1461–1466 (2019). Wigerblad, G. et al. Single-Cell Analysis Reveals the Range of Transcriptional States of 616 33. 617 Circulating Human Neutrophils. The Journal of Immunology 209, 772–782 (2022). 618 Shankland, S. J., Smeets, B., Pippin, J. W. & Moeller, M. J. The emergence of the 34. 619 glomerular parietal epithelial cell. Nature Reviews Nephrology vol. 10 158–173 620 Preprint at https://doi.org/10.1038/nrneph.2014.1 (2014). 621 35. Tran, T. et al. In Vivo Developmental Trajectories of Human Podocyte Inform In Vitro 622 Differentiation of Pluripotent Stem Cell-Derived Podocytes. Dev Cell 50, 102-116.e6 623 (2019). 624 36. Schumacher, A. et al. Defining the variety of cell types in developing and adult human 625 kidneys by single-cell RNA sequencing. npj Regenerative Medicine vol. 6 Preprint at https://doi.org/10.1038/s41536-021-00156-w (2021). 626 Xu, W. *et al.* Mapping of γ/δ T cells reveals V δ 2+ T cells resistance to senescence. 627 37. EBioMedicine 39, 44–58 (2019). 628 629 Marsh, S., Salmon, M. & Hoffman, P. samuel-marsh/scCustomize: Version 2.0.1. 38. 630 Preprint at https://doi.org/10.5281/zenodo.10161832 (2023). 631 Varin, A. Alexis-Varin/RightSeuratTools: RightSeuratTools v1.0.1. Preprint at 39. 632 https://doi.org/10.5281/zenodo.12518909 (2024). 633 40. Matz, M. et al. The regulation of interferon type I pathway-related genes RSAD2 and 634 ETV7 specifically indicates antibody-mediated rejection after kidney transplantation. Clin Transplant 32, e13429 (2018). 635 636 41. Hayde, N. et al. The Clinical and Molecular Significance of C4d Staining Patterns in 637 Renal Allografts. *Transplantation* **95**, (2013). 638 Feng, X. et al. Rabbit ATG but not horse ATG promotes expansion of functional 42. 639 CD4+CD25highFOXP3+ regulatory T cells in vitro. *Blood* 111, 3675–3683 (2008). 640

641

6	4	2
~		_

643 Acknowledgements

We thank the clinical centers of the BIOMARGIN consortium, the clinicians, surgeons, nursing staff and patients. Our special thanks go to Ricard Argelaguet, the first author of the original article describing MOFA, for his precious help with feature selection. We also thank Dr David Hildeman, Krishna Roskin and Babacar Ndao for their help with scRNA-Seg alignment.

648

649

650 Author Contributions Statement

651 C.T., B.L. and M.N. conceived and designed the study. C.T. performed the MOFA analyses.

652 A.V., C.T and B.L. generated, analysed and interpreted the single cell and bulk transcriptomic

data. C.T, D.A., J.C., H.D.L., W.G., P.M., M.R., V.S., E.V.L. and M.N. included patients and

- 654 collected and interpreted the clinical data. C.T., B.L. and M.N. wrote the paper with contribution655 from all co-authors.
- 656

657 Competing Interests Statement

The authors declare no conflict of interest regarding this manuscript.

659

660

661

662 Figures

Fig.1



663

664

Figure 1: Multi-Omics Factor Analysis application on BIOMARGIN datasets identifies important clinical markers in kidney transplantation

(a) Graphical representation of MOFA's matrix decomposition of each view's data into a product composed of a view-specific factor loadings matrix and a shared latent factor matrix. The number of samples ('N') used for multi-omics factor analysis per data set is indicated. The loading of a given factor can be compared a posteriori between patient groups. (b) Number of features ("D") in each view. A grey bar indicates that the sample is missing in the given omic view (c) Total percentage of variance explained (R2) per omic view (d) Percentage of variance explained by each latent factor in the different omic views for the selected MOFA model. (e) Pearson correlation matrix analysis of the 8 latent factors and the various clinical parameters indicated. Positive (+) or negative (-) correlations with the loading of each latent factor are indicated, as well as the log10 p-value resulting from the Pearson correlation tests. Panel a was created using Biorender.com.



Figure 2: Factor 1 discriminates antibody-mediated from T-cell mediated rejection

6

(a-e) Violin plots representing the distribution of latent Factor 1 (a) Global distribution (b) According to Banff cg histological lesions. The difference between groups was assessed by a two-tailed Mann-Whitney test (c) According to Banff i histological lesions. The difference between groups was assessed by a two-tailed Mann-Whitney test (c) According to Banff i histological lesions. The difference between groups was assessed by a two-tailed Mann-Whitney test (d) According to HLA status. The difference between groups was assessed by a two-tailed Mann-Whitney test (d) According to ordinary one-way ANOVA test and multiple comparisons using the Tukey's test. (f) Lollipog graph shows the toop-weighted genes derived from the MicroArray blod dataset in latent Factor 1. (g) Heatmap showing the distribution of the top-weighted genes in the samples. A and B clusters A were determined here in an unsupervised manner.





Figure 3: Factor 2 is associated with complement/monocytes crosstalk (a-b) Violin plots representing the distribution of latent Factor 2 (a) Global distribution (b) According to C4d positivity. The difference between groups was assessed by a two-tailed Mann-Whitney test (c) Lollipop graph shows the top-weighted genes derived from the MicroArray biopsy dataset in latent Factor 2. (d) Heatmap showing the distribution of the topweighted genes explaining Factor 2 in the samples. (e-f) An external validation dataset E-GEOD-38262 was used to confirm the increase of the top-weighted features explaining Factor 2 in C4d positive biopsies. (e) Experimental scheme (f) Volcano plot showing the differentially expressed genes and miRNAs in C4d positive biopsies (N=23). The top-weighted features explaining Factor 2 are indicated. Panel e was created using Biorender.com.





Figure 4: Factor 4 captures the impact of induction prophylaxis

(a-b) Violin plots representing the distribution of latent Factor 4 (a) Global distribution (b) According to induction types. The difference between groups was assessed by a twotailed Mann-Whitney test (c) Lollipop graph shows the top-weighted genes derived from the RNAseq blood dataset in latent Factor 4. (d) Heatmap showing the distribution of the top-weighted genes of Factor 2 in the samples. (e-f) An external validation dataset GSE10040 was used to confirm the decrease of the top-weighted features explaining Factor 4 in PBMC treated with ATG. e) Experimental scheme f) Volcano plot showing the differentially expressed genes in PBMC treated with ATG (N=3) compared to control (N=3). The top-weighted features explaining Factor 4 are indicated. Panel e was created using Biorender.com. ATG, anti thymo globulin ; PBMC, peripheral blood mononuclear cells